Lazuline Biotech

Executive Summary

Lazuline Biotech is a preclinical Indian biotechnology company developing novel antibody-based therapeutics for oncology and immunology. Founded in 2020 and headquartered in Hyderabad, the company leverages advanced antibody engineering platforms, including bispecific antibodies and antibody-drug conjugates (ADCs), to create targeted therapies with improved specificity and reduced off-target effects. Lazuline has raised $15 million in funding and focuses on addressing unmet needs in cancer and autoimmune disorders. With a lean team of 10-50 employees, the company is positioned to advance its pipeline toward clinical development. While still in early stages, Lazuline's platform-driven approach and focus on high-value targets offer potential for differentiation in the competitive immuno-oncology landscape. However, the company faces significant technical and regulatory risks common to preclinical biotechs, and its success hinges on successful IND filings and eventual clinical validation.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead Bispecific Antibody Candidate60% success
• Q3 2026Completion of IND-Enabling Toxicology Studies70% success
• H2 2026Strategic Partnership or Licensing Deal for ADC Platform40% success